zinc sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4275 7733-02-0

Description:

MoleculeDescription

Synonyms:

  • zinc sulfate heptahydrate
  • zinc sulfate
  • zincate
  • sulfuric acid zinc salt
A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
  • Molecular weight: 161.44
  • Formula: O4SZn
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 5, 1987 FDA ABRAXIS PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Systemic lupus erythematosus 119.86 11.82 16 43491 361880 90223060
Glossodynia 114.65 11.82 11 43496 321768 90263172
Maternal exposure during pregnancy 109.99 11.82 20 43487 360043 90224897
Diarrhoea 109.30 11.82 797 42710 938393 89646547
Pericarditis 108.59 11.82 5 43502 270146 90314794
Product dose omission issue 107.51 11.82 346 43161 291341 90293599
Treatment failure 104.13 11.82 12 43495 303916 90281024
Product use in unapproved indication 102.00 11.82 19 43488 336217 90248723
Drug intolerance 96.76 11.82 47 43460 447544 90137396
Wound 96.57 11.82 15 43492 302965 90281975
Off label use 95.66 11.82 246 43261 1102006 89482934
Infusion related reaction 92.80 11.82 42 43465 416738 90168202
Product use issue 89.30 11.82 24 43483 329895 90255045
Helicobacter infection 88.62 11.82 5 43502 226845 90358095
Fall 85.41 11.82 456 43051 481354 90103586
Folliculitis 81.41 11.82 4 43503 204349 90380591
Unevaluable event 78.02 11.82 113 43394 54735 90530205
Deep vein thrombosis 73.27 11.82 146 43361 91474 90493466
Device expulsion 69.81 11.82 92 43415 40794 90544146
Hepatic enzyme increased 69.08 11.82 44 43463 360692 90224248
Arthropathy 68.34 11.82 46 43461 366196 90218744
Type 2 diabetes mellitus 62.65 11.82 11 43496 203233 90381707
Fatigue 62.50 11.82 835 42672 1153188 89431752
Intentional product use issue 62.12 11.82 14 43493 216878 90368062
Full blood count decreased 60.54 11.82 73 43434 29616 90555324
Liver injury 60.27 11.82 6 43501 170561 90414379
Drug ineffective 57.29 11.82 410 43097 1383888 89201052
Drug hypersensitivity 55.00 11.82 86 43421 463523 90121417
Irritable bowel syndrome 54.41 11.82 16 43491 207432 90377508
Therapeutic product effect decreased 54.31 11.82 33 43474 277538 90307402
General physical health deterioration 53.41 11.82 55 43452 355060 90229880
Therapy cessation 53.30 11.82 76 43431 36285 90548655
C-reactive protein increased 51.36 11.82 12 43495 181377 90403563
Device dislocation 50.93 11.82 69 43438 31413 90553527
Haemoglobin decreased 50.67 11.82 182 43325 161774 90423166
Feeling abnormal 49.85 11.82 185 43322 167050 90417890
Nausea 49.17 11.82 776 42731 1109540 89475400
Neuropathy peripheral 49.03 11.82 161 43346 136809 90448131
Lower respiratory tract infection 48.75 11.82 30 43477 250629 90334311
Muscle spasms 46.99 11.82 242 43265 251641 90333299
Constipation 46.62 11.82 261 43246 280134 90304806
Therapeutic product effect incomplete 45.57 11.82 18 43489 193878 90391062
Fibromyalgia 45.52 11.82 21 43486 206248 90378692
Dizziness 44.47 11.82 455 43052 588829 89996111
Blister 43.68 11.82 35 43472 254963 90329977
Pulmonary embolism 43.49 11.82 150 43357 130670 90454270
Impaired healing 42.87 11.82 30 43477 234169 90350771
Dehydration 42.86 11.82 196 43311 194251 90390689
Ill-defined disorder 42.10 11.82 18 43489 184873 90400067
Joint swelling 41.42 11.82 115 43392 503185 90081755
Plasma cell myeloma 41.31 11.82 72 43435 40756 90544184
Urinary tract infection 40.96 11.82 269 43238 305363 90279577
Toxicity to various agents 39.52 11.82 48 43459 287798 90297142
Discomfort 38.46 11.82 45 43462 274290 90310650
Joint range of motion decreased 38.34 11.82 9 43498 135634 90449306
Back pain 36.51 11.82 269 43238 316906 90268034
Prescribed overdose 35.64 11.82 3 43504 97622 90487318
Flatulence 35.58 11.82 68 43439 41299 90543641
Psoriasis 34.86 11.82 152 43355 147602 90437338
Bursitis 34.80 11.82 10 43497 131644 90453296
Asthenia 34.18 11.82 399 43108 533352 90051588
Pneumonia 33.64 11.82 460 43047 637599 89947341
Exposure during pregnancy 33.53 11.82 39 43468 238371 90346569
Dyspnoea 32.43 11.82 598 42909 880357 89704583
Dyspnoea exertional 31.47 11.82 91 43416 72197 90512743
Rheumatoid arthritis 31.21 11.82 81 43426 362533 90222407
Hypoxia 30.42 11.82 90 43417 72309 90512631
Obesity 29.82 11.82 7 43500 105500 90479440
Intentional overdose 29.07 11.82 5 43502 93829 90491111
Grip strength decreased 28.54 11.82 5 43502 92571 90492369
Hypersensitivity 28.43 11.82 117 43390 454560 90130380
Injection site pain 28.38 11.82 161 43346 173538 90411402
Hot flush 27.96 11.82 77 43430 59411 90525529
Headache 27.79 11.82 574 42933 862172 89722768
Alopecia 27.58 11.82 133 43374 494938 90090002
Blood cholesterol increased 27.18 11.82 36 43471 207976 90376964
Peripheral venous disease 27.06 11.82 4 43503 83917 90501023
Pelvic pain 26.90 11.82 35 43472 15322 90569618
Injection site erythema 26.89 11.82 106 43401 98396 90486544
White blood cell count decreased 26.72 11.82 154 43353 166955 90417985
Drug abuse 26.38 11.82 4 43503 82343 90502597
Tremor 26.37 11.82 144 43363 153029 90431911
Cardiac failure congestive 25.97 11.82 105 43402 98589 90486351
Gastrointestinal disorder 25.57 11.82 53 43454 256634 90328306
Vaginal haemorrhage 25.19 11.82 50 43457 31221 90553719
Live birth 24.99 11.82 4 43503 79103 90505837
Injection site haemorrhage 24.91 11.82 47 43460 28271 90556669
Wound infection 24.79 11.82 10 43497 106392 90478548
Sinusitis fungal 24.72 11.82 14 43493 1950 90582990
Blood potassium decreased 24.67 11.82 64 43443 47663 90537277
Atrial fibrillation 24.63 11.82 128 43379 133483 90451457
Balance disorder 24.53 11.82 102 43405 96978 90487962
Hip fracture 24.40 11.82 51 43456 33026 90551914
Salpingo-oophorectomy unilateral 24.27 11.82 11 43496 957 90583983
Sleep disorder 24.15 11.82 36 43471 197994 90386946
Epilepsy 24.15 11.82 5 43502 82201 90502739
International normalised ratio increased 24.00 11.82 63 43444 47253 90537687
Influenza like illness 23.85 11.82 89 43418 80522 90504418
Respiratory symptom 23.23 11.82 18 43489 4234 90580706
Pleural effusion 22.55 11.82 110 43397 111881 90473059
Laboratory test abnormal 22.54 11.82 57 43450 41797 90543143
Mobility decreased 22.34 11.82 55 43452 250679 90334261
Swelling 21.95 11.82 115 43392 418943 90165997
Hypervolaemia 21.30 11.82 48 43459 32709 90552231
Embolism venous 21.26 11.82 16 43491 3604 90581336
Platelet count decreased 21.09 11.82 125 43382 136844 90448096
Anaemia 20.90 11.82 260 43247 352542 90232398
Infection 20.90 11.82 96 43411 361998 90222942
Dysgeusia 20.82 11.82 64 43443 52496 90532444
Pulmonary fibrosis 20.70 11.82 13 43494 107490 90477450
Red blood cell sedimentation rate increased 20.52 11.82 7 43500 82588 90502352
Skin discolouration 20.47 11.82 57 43450 44258 90540682
Tricuspid valve incompetence 20.27 11.82 32 43475 16699 90568241
Oedema peripheral 20.27 11.82 201 43306 257714 90327226
Adverse event 20.24 11.82 16 43491 117402 90467538
Eye swelling 20.17 11.82 44 43463 29342 90555598
Condition aggravated 20.05 11.82 186 43321 595359 89989581
Chills 20.04 11.82 120 43387 131861 90453079
Pulmonary hypertension 19.94 11.82 55 43452 42468 90542472
Sputum increased 19.46 11.82 14 43493 2943 90581997
Thrombosis 19.33 11.82 78 43429 73173 90511767
Nasal congestion 19.05 11.82 85 43422 83329 90501611
Pulmonary arterial hypertension 18.88 11.82 40 43467 26147 90558793
Abdominal discomfort 18.81 11.82 143 43364 477185 90107755
Flushing 18.59 11.82 88 43419 88403 90496537
Inflammation 18.53 11.82 36 43471 178556 90406384
COVID-19 18.43 11.82 33 43474 168810 90416130
Wheezing 18.38 11.82 56 43451 238024 90346916
Autoimmune disorder 18.23 11.82 7 43500 76737 90508203
Stomatitis 18.22 11.82 69 43438 274629 90310311
Chest discomfort 18.03 11.82 121 43386 138244 90446696
Product complaint 18.01 11.82 27 43480 13473 90571467
Overdose 17.96 11.82 30 43477 157679 90427261
Hypertension 17.58 11.82 138 43369 457394 90127546
Lung disorder 17.55 11.82 28 43479 149855 90435085
Dry skin 17.37 11.82 86 43421 87987 90496953
Abdominal pain 17.15 11.82 276 43231 395445 90189495
Multiple sclerosis relapse 16.53 11.82 59 43448 52246 90532694
Suicide attempt 16.13 11.82 8 43499 75391 90509549
Fluid retention 15.96 11.82 84 43423 88007 90496933
Asthma 15.95 11.82 61 43446 242099 90342841
Acute respiratory failure 15.84 11.82 51 43456 42867 90542073
Haematocrit decreased 15.70 11.82 50 43457 41782 90543158
Illness 15.66 11.82 10 43497 81959 90502981
Vision blurred 15.31 11.82 98 43409 110195 90474745
Hospice care 15.28 11.82 21 43486 9683 90575257
Gallbladder disorder 15.15 11.82 31 43476 19772 90565168
Cellulitis 15.13 11.82 85 43422 91252 90493688
Injection site mass 15.07 11.82 33 43474 22057 90562883
Lethargy 14.91 11.82 65 43442 63074 90521866
Diastolic dysfunction 14.90 11.82 18 43489 7315 90577625
Pollakiuria 14.80 11.82 42 43465 32963 90551977
Body height decreased 14.68 11.82 23 43484 11926 90573014
Mental status changes 14.63 11.82 51 43456 44628 90540312
Myalgia 14.50 11.82 138 43369 174987 90409953
Administration site swelling 14.46 11.82 9 43498 1490 90583450
Red blood cell count decreased 14.40 11.82 52 43455 46299 90538641
Cough 14.40 11.82 253 43254 368709 90216231
Tooth disorder 14.37 11.82 40 43467 31050 90553890
Night sweats 14.20 11.82 25 43482 128741 90456199
Bone pain 14.03 11.82 63 43444 61920 90523020
Drug-induced liver injury 13.54 11.82 14 43493 90304 90494636
Hypophagia 13.53 11.82 43 43464 35894 90549046
Blepharospasm 13.26 11.82 5 43502 55440 90529500
Pulmonary oedema 13.23 11.82 62 43445 62018 90522922
Plasma cell myeloma recurrent 13.17 11.82 13 43494 4215 90580725
Intestinal dilatation 13.10 11.82 10 43497 2300 90582640
Hiatus hernia 13.10 11.82 34 43473 25327 90559613
Cardiac disorder 13.02 11.82 58 43449 56814 90528126
Malnutrition 12.98 11.82 28 43479 18530 90566410
Aspartate aminotransferase increased 12.80 11.82 89 43418 102848 90482092
Cardiac pacemaker insertion 12.72 11.82 13 43494 4394 90580546
Restless legs syndrome 12.52 11.82 31 43476 22439 90562501
Injection site bruising 12.47 11.82 54 43453 52253 90532687
Depression 12.40 11.82 208 43299 300393 90284547
Swelling face 12.36 11.82 74 43433 81278 90503662
Decubitus ulcer 12.17 11.82 21 43486 11792 90573148
Heavy menstrual bleeding 12.16 11.82 29 43478 20501 90564439
Ageusia 12.11 11.82 25 43482 16051 90568889
Complication associated with device 12.09 11.82 28 43479 19421 90565519
Multiple sclerosis 12.07 11.82 35 43472 27805 90557135
Musculoskeletal stiffness 12.06 11.82 88 43419 296444 90288496
Epistaxis 12.03 11.82 76 43431 85049 90499891
Multiple allergies 11.93 11.82 24 43483 15122 90569818
Occult blood positive 11.85 11.82 12 43495 4011 90580929
Foetal exposure during pregnancy 11.85 11.82 3 43504 42972 90541968

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 99.17 12.80 149 25935 638186 41957065
Product use in unapproved indication 74.18 12.80 12 26072 184444 42410807
Anal inflammation 70.35 12.80 32 26052 2197 42593054
SARS-CoV-2 test negative 67.35 12.80 29 26055 1746 42593505
Fatigue 53.89 12.80 452 25632 435189 42160062
Diarrhoea 52.75 12.80 470 25614 460379 42134872
Plasma cell myeloma 52.60 12.80 100 25984 47478 42547773
Respiratory tract infection bacterial 46.72 12.80 23 26061 1886 42593365
Drug interaction 45.54 12.80 58 26026 266941 42328310
Accident 45.09 12.80 35 26049 6468 42588783
Proctalgia 42.41 12.80 35 26049 7058 42588193
Completed suicide 41.75 12.80 5 26079 96460 42498791
Full blood count decreased 38.74 12.80 55 26029 20505 42574746
Body temperature increased 37.69 12.80 54 26030 20304 42574947
Asthenia 37.10 12.80 296 25788 280497 42314754
Laboratory test abnormal 36.87 12.80 57 26027 22921 42572330
Respiratory tract infection viral 36.74 12.80 24 26060 3382 42591869
Toxicity to various agents 35.81 12.80 53 26031 229083 42366168
Drug ineffective 35.20 12.80 234 25850 629963 41965288
White blood cell count decreased 34.96 12.80 147 25937 110249 42485002
Product dose omission issue 34.64 12.80 186 25898 154179 42441072
Fall 30.82 12.80 247 25837 234273 42360978
Adverse drug reaction 26.78 12.80 66 26018 37368 42557883
Back pain 26.03 12.80 162 25922 141614 42453637
Chills 23.61 12.80 117 25967 93949 42501302
Pneumonia 22.97 12.80 374 25710 421775 42173476
Intentional product misuse 22.78 12.80 5 26079 61895 42533356
Platelet count decreased 22.77 12.80 154 25930 138427 42456824
General physical health deterioration 21.69 12.80 37 26047 151209 42444042
Dizziness 21.46 12.80 240 25844 249014 42346237
Treatment failure 21.22 12.80 6 26078 62618 42532633
Overdose 21.07 12.80 20 26064 105244 42490007
Viral infection 20.93 12.80 44 26040 22439 42572812
Therapy cessation 20.18 12.80 41 26043 20409 42574842
Interstitial lung disease 19.40 12.80 12 26072 78450 42516801
Muscle spasms 18.14 12.80 102 25982 85942 42509309
Psoriasis 18.00 12.80 68 26016 48536 42546715
Influenza 17.53 12.80 80 26004 62095 42533156
Foetal exposure during pregnancy 17.05 12.80 4 26080 47307 42547944
Regurgitation 16.95 12.80 12 26072 1928 42593323
Sinusitis 16.56 12.80 65 26019 47227 42548024
Peripheral swelling 16.45 12.80 103 25981 90167 42505084
Neuropathy peripheral 16.01 12.80 112 25972 101741 42493510
Haemoglobin decreased 16.01 12.80 137 25947 132334 42462917
Eructation 15.59 12.80 18 26066 5468 42589783
Multiple organ dysfunction syndrome 15.57 12.80 22 26062 97013 42498238
Cardiac disorder 15.34 12.80 65 26019 48867 42546384
Rash 14.87 12.80 245 25839 276709 42318542
Influenza like illness 14.77 12.80 48 26036 31792 42563459
Unevaluable event 14.41 12.80 50 26034 34238 42561013
Dehydration 14.29 12.80 141 25943 141626 42453625
Hepatic function abnormal 14.03 12.80 7 26077 51560 42543691
Constipation 13.82 12.80 156 25928 162135 42433116
Memory impairment 13.70 12.80 64 26020 50158 42545093
Therapeutic product effect incomplete 13.59 12.80 14 26070 70925 42524326
Coma 13.51 12.80 8 26076 53546 42541705
Mental status changes 13.25 12.80 56 26028 42059 42553192
Small intestinal obstruction 13.18 12.80 31 26053 17030 42578221
Haematocrit decreased 13.06 12.80 49 26035 34859 42560392
Suicide attempt 12.93 12.80 6 26078 46094 42549157

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 152.61 10.98 328 54993 1499857 109034121
Product use in unapproved indication 146.57 10.98 24 55297 447353 110086625
Contraindicated product administered 110.16 10.98 3 55318 248264 110285714
Treatment failure 105.22 10.98 9 55312 277225 110256753
Product dose omission issue 98.48 10.98 369 54952 321413 110212565
Completed suicide 97.33 10.98 6 55315 242375 110291603
Systemic lupus erythematosus 91.92 10.98 10 55311 254328 110279650
Diarrhoea 91.55 10.98 920 54401 1138585 109395393
Drug intolerance 90.71 10.98 45 55276 406467 110127511
Fall 88.51 10.98 560 54761 602922 109931056
Drug ineffective 78.53 10.98 444 54877 1520096 109013882
Device expulsion 77.12 10.98 86 55235 30805 110503173
Product use issue 73.39 10.98 32 55289 311663 110222315
Duodenal ulcer perforation 72.55 10.98 4 55317 177696 110356282
Glossodynia 72.44 10.98 12 55309 221992 110311986
Deep vein thrombosis 71.90 10.98 192 55129 139695 110394283
Helicobacter infection 71.54 10.98 5 55316 181872 110352106
Infusion related reaction 69.99 10.98 53 55268 381109 110152869
Anal inflammation 69.83 10.98 31 55290 2465 110531513
Plasma cell myeloma 69.46 10.98 118 55203 62818 110471160
Drug abuse 69.43 10.98 5 55316 177406 110356572
Therapy cessation 68.96 10.98 98 55223 44759 110489219
Maternal exposure during pregnancy 68.73 10.98 21 55300 254862 110279116
Toxicity to various agents 67.24 10.98 85 55236 480470 110053508
SARS-CoV-2 test negative 64.31 10.98 28 55293 2125 110531853
Pericarditis 62.90 10.98 16 55305 219098 110314880
Folliculitis 62.10 10.98 6 55315 167647 110366331
Fatigue 62.05 10.98 901 54420 1215057 109318921
General physical health deterioration 59.72 10.98 75 55246 425220 110108758
Dizziness 59.39 10.98 571 54750 697622 109836356
Drug hypersensitivity 57.80 10.98 86 55235 454004 110079974
Dehydration 57.25 10.98 284 55037 279227 110254751
Haemoglobin decreased 55.47 10.98 259 55062 248468 110285510
Asthenia 55.43 10.98 557 54764 688442 109845536
Irritable bowel syndrome 51.14 10.98 10 55311 164205 110369773
Therapeutic product effect incomplete 51.07 10.98 24 55297 223781 110310197
Full blood count decreased 50.63 10.98 71 55250 32028 110501950
C-reactive protein increased 48.76 10.98 24 55297 217895 110316083
Wound 47.83 10.98 29 55292 234408 110299570
Lower respiratory tract infection 46.96 10.98 32 55289 243074 110290904
Drug interaction 46.76 10.98 114 55207 500069 110033909
Arthropathy 46.63 10.98 45 55276 287477 110246501
Unevaluable event 46.53 10.98 96 55225 59131 110474847
Fibromyalgia 46.21 10.98 14 55307 170895 110363083
Respiratory tract infection bacterial 45.97 10.98 23 55298 2393 110531585
Intentional overdose 45.90 10.98 6 55315 132495 110401483
Pulmonary embolism 45.39 10.98 220 55101 214254 110319724
Type 2 diabetes mellitus 45.31 10.98 16 55305 177216 110356762
Hepatic enzyme increased 44.60 10.98 57 55264 320835 110213143
Device dislocation 43.99 10.98 66 55255 31638 110502340
Chills 43.62 10.98 200 55121 190380 110343598
Intentional product use issue 43.56 10.98 36 55285 247870 110286108
Liver injury 43.13 10.98 11 55310 150402 110383576
Joint swelling 42.12 10.98 100 55221 442745 110091233
Dyspnoea 40.76 10.98 778 54543 1106094 109427884
Proctalgia 40.42 10.98 41 55280 13181 110520797
Feeling abnormal 40.14 10.98 188 55133 180523 110353455
Dyspnoea exertional 38.38 10.98 127 55194 103933 110430045
Back pain 37.92 10.98 316 55005 370680 110163298
Intentional product misuse 37.57 10.98 10 55311 132894 110401084
Accident 37.26 10.98 36 55285 10916 110523062
Mental status changes 35.64 10.98 101 55220 76021 110457957
Nausea 35.59 10.98 838 54483 1234852 109299126
Ill-defined disorder 35.50 10.98 17 55304 156836 110377142
Pneumonia 35.28 10.98 625 54696 876089 109657889
Hypervolaemia 35.19 10.98 77 55244 49383 110484595
Bursitis 34.48 10.98 11 55310 129907 110404071
International normalised ratio increased 33.89 10.98 108 55213 86664 110447314
Hypoxia 33.49 10.98 141 55180 129374 110404604
Therapeutic product effect decreased 33.32 10.98 44 55277 244272 110289706
Aspartate aminotransferase increased 32.36 10.98 162 55159 159774 110374204
Overdose 31.99 10.98 42 55279 233752 110300226
Platelet count decreased 31.91 10.98 211 55110 230232 110303746
Respiratory tract infection viral 31.45 10.98 25 55296 5853 110528125
Haematocrit decreased 31.22 10.98 88 55233 66029 110467949
Joint range of motion decreased 31.14 10.98 11 55310 121821 110412157
Blister 30.96 10.98 41 55280 227335 110306643
Rheumatoid arthritis 30.64 10.98 65 55256 299548 110234430
Muscle spasms 30.62 10.98 241 55080 277916 110256062
Cardiac failure congestive 30.58 10.98 153 55168 150847 110383131
White blood cell count decreased 30.54 10.98 208 55113 229182 110304796
Prescribed overdose 30.25 10.98 4 55317 87577 110446401
Hypercholesterolaemia 29.42 10.98 5 55316 90832 110443146
Hip fracture 28.82 10.98 58 55263 35093 110498885
Peripheral venous disease 28.68 10.98 4 55317 84113 110449865
Fluid retention 28.66 10.98 108 55213 94199 110439779
Urinary tract infection 28.22 10.98 268 55053 326014 110207964
Hospice care 28.21 10.98 33 55288 12440 110521538
Obesity 27.68 10.98 11 55310 113340 110420638
Blood potassium decreased 27.51 10.98 74 55247 54040 110479938
Epilepsy 27.46 10.98 8 55313 100201 110433777
Grip strength decreased 26.90 10.98 4 55317 80170 110453808
Gastrointestinal disorder 26.88 10.98 50 55271 241902 110292076
Myelosuppression 26.85 10.98 7 55314 94333 110439645
Constipation 26.67 10.98 285 55036 357501 110176477
Flatulence 26.19 10.98 71 55250 52078 110481900
Exposure during pregnancy 25.10 10.98 28 55293 167396 110366582
Influenza like illness 25.03 10.98 99 55222 88313 110445665
Pleural effusion 24.77 10.98 163 55158 177546 110356432
Pelvic pain 24.75 10.98 35 55286 15907 110518071
Mobility decreased 24.70 10.98 51 55270 237371 110296607
Impaired healing 24.28 10.98 38 55283 196679 110337299
Multiple sclerosis relapse 23.85 10.98 67 55254 50173 110483805
Oedema peripheral 23.66 10.98 260 55061 328400 110205578
Tremor 23.23 10.98 177 55144 202055 110331923
Small intestinal obstruction 22.74 10.98 50 55271 32163 110501815
Pulmonary hypertension 22.73 10.98 70 55251 55150 110478828
Viral infection 22.47 10.98 68 55253 53071 110480907
Discomfort 22.43 10.98 46 55275 214661 110319317
Inflammation 22.30 10.98 39 55282 193199 110340779
Headache 22.22 10.98 588 54733 881789 109652189
Salpingo-oophorectomy unilateral 22.22 10.98 10 55311 821 110533157
Suicide attempt 22.20 10.98 12 55309 103382 110430596
Abdominal pain 22.12 10.98 370 54951 512619 110021359
Live birth 22.12 10.98 4 55317 69480 110464498
Injection site pain 21.73 10.98 158 55163 177764 110356214
Injection site erythema 21.66 10.98 99 55222 94077 110439901
Vaginal haemorrhage 21.31 10.98 42 55279 25032 110508946
Pulmonary arterial hypertension 21.26 10.98 49 55272 32519 110501459
Sleep disorder 21.23 10.98 42 55279 198602 110335376
Dysgeusia 21.14 10.98 80 55241 69905 110464073
Lung disorder 21.08 10.98 36 55285 180011 110353967
Therapeutic response decreased 21.02 10.98 11 55310 96488 110437490
Autoimmune disorder 20.35 10.98 4 55317 65479 110468499
Cellulitis 20.32 10.98 120 55201 125896 110408082
Acute respiratory failure 20.28 10.98 83 55238 75177 110458801
Gastrointestinal haemorrhage 20.22 10.98 147 55174 165371 110368607
Condition aggravated 20.20 10.98 253 55068 734583 109799395
Complication associated with device 20.01 10.98 36 55285 20037 110513941
Injection site haemorrhage 19.72 10.98 48 55273 32980 110500998
Flushing 19.72 10.98 104 55217 104632 110429346
Coma 19.62 10.98 18 55303 117851 110416127
Wound infection 19.57 10.98 12 55309 96453 110437525
Body temperature increased 19.48 10.98 66 55255 54647 110479331
Product complaint 19.26 10.98 29 55292 13943 110520035
Eosinophilia 19.18 10.98 3 55318 57933 110476045
Atrial fibrillation 19.04 10.98 187 55134 229455 110304523
Cardiac disorder 18.90 10.98 82 55239 76198 110457780
Cytokine release syndrome 18.57 10.98 6 55315 70300 110463678
Stomatitis 18.50 10.98 71 55250 270171 110263807
Alanine aminotransferase increased 18.46 10.98 156 55165 183617 110350361
Illness 18.44 10.98 9 55312 82162 110451816
Drug-induced liver injury 18.08 10.98 20 55301 120047 110413931
Neuropathy peripheral 17.92 10.98 152 55169 179125 110354853
Hypertension 17.87 10.98 166 55155 509918 110024060
Eructation 17.73 10.98 28 55293 14029 110519949
Sinusitis fungal 17.70 10.98 13 55308 2707 110531271
COVID-19 17.68 10.98 63 55258 244997 110288981
Asthma 17.63 10.98 65 55256 250226 110283752
Eye swelling 17.61 10.98 46 55275 33002 110500976
Transfusion 17.38 10.98 39 55282 25433 110508545
Red blood cell count decreased 17.21 10.98 72 55249 65851 110468127
Death 17.08 10.98 464 54857 698405 109835573
Hepatic function abnormal 16.91 10.98 12 55309 89283 110444695
Alopecia 16.84 10.98 110 55211 364643 110169335
Infection 16.84 10.98 109 55212 362091 110171887
Tricuspid valve incompetence 16.79 10.98 37 55284 23836 110510142
Nasal congestion 16.76 10.98 95 55226 98187 110435791
Blood cholesterol increased 16.55 10.98 43 55278 184742 110349236
Pulmonary fibrosis 16.49 10.98 16 55305 102026 110431952
Cholestasis 16.19 10.98 6 55315 64512 110469466
Hypersensitivity 16.15 10.98 127 55194 403871 110130107
Blepharospasm 15.74 10.98 4 55317 54847 110479131
Lethargy 15.66 10.98 90 55231 93486 110440492
Laryngeal pain 15.54 10.98 17 55304 5958 110528020
Atelectasis 15.54 10.98 47 55274 36665 110497313
Red blood cell sedimentation rate increased 15.52 10.98 10 55311 78292 110455686
Agranulocytosis 15.07 10.98 6 55315 61754 110472224
Hypophagia 14.95 10.98 59 55262 52567 110481411
Bronchitis 14.57 10.98 131 55190 156901 110377077
Malnutrition 14.57 10.98 38 55283 27241 110506737
Weight decreased 14.49 10.98 321 55000 467736 110066242
Wheezing 14.46 10.98 72 55249 255158 110278820
Disease progression 14.44 10.98 186 55135 243848 110290130
Pain in jaw 14.23 10.98 57 55264 51120 110482858
Anaemia 14.15 10.98 366 54955 546720 109987258
Gallbladder disorder 14.12 10.98 32 55289 20997 110512981
Infective pulmonary exacerbation of cystic fibrosis 14.10 10.98 26 55295 14745 110519233
Bone erosion 14.06 10.98 3 55318 46368 110487610
Balance disorder 13.93 10.98 103 55218 116457 110417521
Bone pain 13.90 10.98 67 55254 65066 110468912
Cytomegalovirus infection 13.76 10.98 5 55316 54439 110479539
Blood glucose decreased 13.67 10.98 39 55282 29449 110504529
Hepatitis 13.56 10.98 15 55306 90039 110443939
Nail disorder 13.54 10.98 6 55315 57929 110476049
Drug ineffective for unapproved indication 13.53 10.98 19 55302 102819 110431159
Heavy menstrual bleeding 13.41 10.98 27 55294 16338 110517640
Chest pain 13.23 10.98 263 55058 376112 110157866
Thrombosis 12.98 10.98 96 55225 108566 110425412
Depression 12.98 10.98 227 55094 317108 110216870
Application site erythema 12.95 10.98 15 55306 5595 110528383
Night sweats 12.92 10.98 30 55291 133953 110400025
Drug resistance 12.92 10.98 6 55315 56368 110477610
Sleep disorder due to a general medical condition 12.82 10.98 5 55316 52107 110481871
Liver disorder 12.81 10.98 33 55288 142210 110391768
Interstitial lung disease 12.80 10.98 32 55289 139302 110394676
Hospitalisation 12.78 10.98 118 55203 142375 110391603
Sputum increased 12.65 10.98 15 55306 5736 110528242
Anaphylactic shock 12.59 10.98 5 55316 51541 110482437
Occult blood positive 12.54 10.98 17 55304 7428 110526550
Swelling 12.39 10.98 114 55207 350927 110183051
Dialysis 12.24 10.98 29 55292 19590 110514388
Myalgia 12.12 10.98 167 55154 222214 110311764
Blood glucose increased 12.02 10.98 110 55211 132386 110401592
Failure to thrive 11.85 10.98 23 55298 13551 110520427
Rotator cuff syndrome 11.78 10.98 26 55295 16768 110517210
Injection site nodule 11.71 10.98 13 55308 4633 110529345
Granulocytopenia 11.66 10.98 22 55299 12693 110521285
Application site discolouration 11.66 10.98 7 55314 1042 110532936
Cardiac pacemaker insertion 11.55 10.98 15 55306 6286 110527692
Application site pain 11.53 10.98 14 55307 5485 110528493
Lymphopenia 11.39 10.98 3 55318 40167 110493811
Foot deformity 11.36 10.98 5 55316 48475 110485503
Model for end stage liver disease score increased 11.21 10.98 3 55318 50 110533928
Psoriasis 11.11 10.98 113 55208 139880 110394098
Abdominal distension 11.01 10.98 135 55186 174968 110359010
Regurgitation 11.01 10.98 11 55310 3474 110530504

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A12CB01 ALIMENTARY TRACT AND METABOLISM
MINERAL SUPPLEMENTS
OTHER MINERAL SUPPLEMENTS
Zinc
ATC B05XA18 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Electrolyte solutions
MeSH PA D001252 Astringents
MeSH PA D003879 Dermatologic Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33287 fertilizer
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

A12CB Zinc 1 drug
zinc gluconate
B05XA Electrolyte solutions 18 drugs
ammonium chloridecalcium chloridecalcium gluconatehydrochloric acidmagnesium chloridemagnesium phosphatemagnesium sulfatepotassium acetatepotassium chloridepotassium lactatepotassium phosphatesodium acetate show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Red eye indication 75705005
Zinc deficiency indication 238124008
Hereditary acrodermatitis enteropathica off-label use 37702000
Viral gastroenteritis off-label use 111843007
Impotence off-label use 397803000
Attention deficit hyperactivity disorder off-label use 406506008
Hypocupremia contraindication 19577007
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Heart disease contraindication 56265001 DOID:114
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypercalciuria contraindication 71938000
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Eye infection contraindication 128351009
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Injury of eye region contraindication 282752000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Psychiatric Disturbance contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML) TRALEMENT AM REGENT N209376 July 2, 2020 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML) TRALEMENT AM REGENT N209376 Dec. 2, 2020 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 11975022 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 12150956 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML) MULTRYS AM REGENT N209376 June 30, 2021 RX SOLUTION INTRAVENOUS 12150957 July 1, 2041 NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017710 VUID
N0000146080 NUI
D06371 KEGG_DRUG
7446-20-0 SECONDARY_CAS_RN
4017651 VANDF
4017710 VANDF
C0078794 UMLSCUI
CHEBI:32312 CHEBI
CHEMBL1200929 ChEMBL_ID
D019287 MESH_DESCRIPTOR_UI
DB09322 DRUGBANK_ID
24424 PUBCHEM_CID
1311282 RXNORM
1512 MMSL
21079 MMSL
5710 MMSL
72010 MMSL
7398 MMSL
d04057 MMSL
000844 NDDF
001944 NDDF
007499 NDDF
387367007 SNOMEDCT_US
6625006 SNOMEDCT_US
N57JI2K7WP UNII
N57JI2K7WP INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Multitrace-5 HUMAN PRESCRIPTION DRUG LABEL 5 0517-8510 INJECTION, SOLUTION 4.39 mg INTRAVENOUS UNAPPROVED DRUG OTHER 14 sections
Multitrace -4 Pediatric HUMAN PRESCRIPTION DRUG LABEL 4 0517-9203 INJECTION, SOLUTION, CONCENTRATE 4.39 mg INTRAVENOUS UNAPPROVED DRUG OTHER 14 sections